Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05140525 · ClinicalTrials.gov registry record · Phase 3
Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPH
A Phase 3 study of CTEPH, sponsored by Dr Sudarshan Rajagopal.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT05140525 is a Phase 3 study of CTEPH that is actively recruiting participants, run by Dr Sudarshan Rajagopal. The registered enrollment target is 15 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05140525, a Phase 3 study of CTEPH, is actively recruiting participants, sponsored by Dr Sudarshan Rajagopal.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The main goal of this study is to determine the effects of combination medical therapy (Riociguat and Macitentan) and balloon pulmonary angioplasty (BPA) on hemodynamics and right ventricular (RV) function (including advanced assessments of RV-pulmonary artery (PA) coupling from invasive hemodynamics) in participants with inoperable or post-PTE residual CTEPH.
Conditions Studied
Interventions
- DRUG Macitentan Tablets
- DRUG Riociguat
- DEVICE balloon pulmonary angioplasty
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2025-01-27 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05140525
The ClinicalTrials.gov registry entry for NCT05140525 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dr Sudarshan Rajagopal, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with CTEPH appearing as the primary indexed condition, and to 3 interventions - of which Macitentan Tablets is the first listed.
NCT05140525 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT05140525 about?
NCT05140525 is a clinical study titled "Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPH". The main goal of this study is to determine the effects of combination medical therapy (Riociguat and Macitentan) and balloon pulmonary angioplasty (BPA) on hemodynamics and right ventricular (RV) function (including advanced assessments of RV-pulmonary artery (PA) coupling from invasive hemodynamic...
What is the current status of trial NCT05140525?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 15 participants. The study started on 2025-01-27. Estimated completion is 2026-12-31.
What conditions does trial NCT05140525 study?
This clinical trial studies the following conditions: CTEPH.
What interventions are being tested in trial NCT05140525?
The interventions under investigation include: Macitentan Tablets (DRUG), Riociguat (DRUG), balloon pulmonary angioplasty (DEVICE).
Who is sponsoring clinical trial NCT05140525?
This trial is sponsored by Dr Sudarshan Rajagopal, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05140525 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for CTEPH
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.